2240
Y. Wang et al. / Tetrahedron Letters 48 (2007) 2237–2240
ielski, M.; Pufky, D.; Doring, M. Tetrahedron 2005, 61,
References and notes
5942–5947; (c) Cucek, K.; Vercek, B. Synlett 1994, 667–668;
(d) Ramalingam, T.; Murty, M. S. R.; Nageswar, Y. V. D.;
Sattur, P. B. J. Heterocycl. Chem. 1990, 27, 981; (e)
Bourgeois, P.; Cantegril, R.; Chene, A.; Gelin, J.; Mortier,
J.; Moyroud, J. Synth. Commun. 1993, 23, 3195–3199.
8. Method A: 0.1 mmol of acid 6 and 0.1 mmol of 7 were
added to a microwave tube containing 0.3 mmol of PS-
PPh3 in 1 ml solvent. 0.2 mmol DIEA was also added for
entries 2 and 6. Finally 0.2 mmol CCl3CN was added. The
mixture was heated in microwave at 150 °C for 15 min;
Method B: 0.1 mmol of acid 6 was added to a microwave
tube containing 0.3 mmol of PS-PPh3 in 1 ml solvent
followed by 0.2 mmol CCl3CN. The mixture was heated
in microwave at 100 °C for 5 min. The microwave tube was
uncapped and 0.1 mmol 7 was added to the above mixture
followed by 0.2 mmol DIEA (entries 3–5). The mixture was
recapped and was heated again in microwave at 150 °C for
15 min; Method C: same as method B except 0.12 mmol of
CCl3CN was added.
9. General procedure: A Smith process vial (0.5–2 ml) was
charged with a stir bar. To the vessel were added 0.2 mmol
of the carboxylic acid and 0.2 mmol of the 2-hydrazino-
pyridine in 1.5 ml dry CH2Cl2. 0.6 mmol PS-PPh3 (3 mmol/
g) was added to the reaction mixture followed by 0.4 mmol
DIEA and 0.4 mmol CCl3CN. The reaction vessel was
sealed and heated in a microwave oven to 150 °C for
15 min. After cooling, the reaction vessel was uncapped and
the resin was filtered and washed by additional CH2Cl2 and
MeOH. The desired product triazolopyridine was isolated
by reverse-phase HPLC. All products thus obtained were
greater than 95% pure as determined by LC/MS and NMR
analysis.
1. For some reviews, see: (a) Bleicher, K. H.; Bohm, H.;
Muller, K.; Alanine, A. Nature Rev. 2003, 2, 369–378; (b)
¨
Hann, M. M.; Leach, A. R.; Harper, G. J. Chem. Inf.
Comput. Sci. 2001, 41, 856–864; (c) Oprea, T. I.; Davis, A.
M.; Teague, S. J.; Leeson, P. D. J. Chem. Inf. Comput. Sci.
2001, 41, 1308–1315.
2. Wang, Y.; Miller, R. L.; Sauer, D. R.; Djuric, S. W. Org.
Lett. 2005, 7, 925–928.
3. Wang, Y.; Sauer, D. R.; Djuric, S. W. Tetrahedron Lett.
2006, 47, 105–108.
4. Wang, Y.; Sarris, K.; Sauer, D. R.; Djuric, S. W.
Tetrahedron Lett. 2006, 47, 4823–4826.
5. For the use of CCl3CN/PS-PPh3 in acylation, see: (a) Jang,
D. O.; Park, D. J.; Kim, J. Tetrahedron Lett. 1999, 43,
5323–5326; (b) Buchstaller, H.; Ebert, H. M.; Anlauf, U.
Synth. Commun. 2001, 31, 1001–1005.
6. For some examples, see: (a) McClure, K. F.; Abramov, Y.
A.; Laird, E. R.; Barberia, J. T.; Cai, W.; Carty, T. J., et al.
J. Med. Chem. 2005, 48, 5728–5737; (b) Kim, D.; Wang, L.;
Hale, J. J.; Lynch, C. L.; Budhu, R. J.; MacCoss, M., et al.
Bioorg. Med. Chem. Lett. 2005, 15, 2129–2134; (c) Savini,
L.; Chiasserini, L.; Pellerano, C.; Filippelli, W.; Falcone, G.
Farmaco 2001, 56, 939–945; (d) Brown, D. J.; Iwai, Y. Aust.
J. Chem. 1979, 32, 2727–2733; (e) Sadana, A. K.; Mirza, Y.;
Aneja, K. R.; Prakash, O. Eur. J. Med. Chem. 2003, 38,
533–536; (f) Peignier, R.; Chene, A.; Cantegril, R.; Mortier,
J. Eur. Pat. Appl. 441718, 1991; (g) Sarges, S.; Howard, H.
R.; Browne, R. G.; lebel, L. A.; Seymour, P. A.; Koe, B. K.
J. Med. Chem. 1990, 33, 2240–2254.
7. For some recent examples, see: (a) Moulin, A.; Martinez, J.;
Fehrentz, J. Tetrahedron Lett. 2006, 7591–7594; (b) Cies-